It seems as though every few weeks, we see more and more alternative channels being used for contact lens distribution and sales, some of which are being done in ways that appear to be outside of proper examination and prescription requirements. Technology is certainly pushing limits and challenging normal expectations and standards in eye care. We would like to hear and potentially share your thoughts. Please email us at email@example.com.
Jason J. Nichols, OD, MPH, PhD
Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
Avedro, Inc. announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns is president, CEO, and a member of the board of directors at Glaukos Corporation.
Mr. Burns has more than 25 years of direct ophthalmic management experience, including more than 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, and surgical products. Over his career, he has raised nearly $400 million in private offerings and in the public markets. Prior to Glaukos, Mr. Burns led Eyetech Pharmaceuticals (acquired by OSI Pharmaceuticals) as president, COO, and as a director. He is currently chairman of Dose Medical Inc.
Waldo Secures $5 Million in Series A Venture Capital Funding
Waldo, a London-based direct-to-consumer contact lens brand, secured $5 million in Series A venture capital funding. Backers included PROfounders Capital, YYX Ventures, Tectonic Capital, and Tinder co-founders Sean Rad and Justin Mateen in the United States.
The company intends to use the funds to accelerate ongoing international expansion in Europe and the United States.
Opternative Adds Chief Marketing Officer to Leadership Team
Opternative, Inc. announced that Lori McInerney has joined the company as chief marketing officer. In the role, she will lead the marketing team in driving brand awareness globally, growing partner marketing, and bringing in new business.
Prior to joining Opternative, Ms. McInerney was the vice president of marketing at Shiftgig, where she and her team were responsible for driving new business via targeted content and thought leadership, increasing brand awareness and public relations, and recruiting on-demand talent. She also spent more than 10 years at CareerBuilder in various marketing and sales leadership roles.
EyePoint Pharmaceuticals Appoints David Price as CFO
EyePoint Pharmaceuticals, Inc. appointed David Price as CFO, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities.
He brings to EyePoint more than 25 years of financial experience in executing debt and equity capital financings, business development deals, restructurings, and oversight of all financial functions in both domestic and international markets for public and private commercial companies. Previously, Mr. Price has held CFO positions at Concordia International Corporation, Bioventus, Cornerstone Therapeutics Inc, and Edgar Online, Inc.
Guardion Health Sciences Receives Methods Patents to Standardize Vision Testing
Guardion Health Sciences, Inc. was issued two patents by the U.S. Patent and Trademark Office, both titled Method and Apparatus for Visual Acuity Testing. The first patent targeted automatic light calibration of the display screens used for vision testing, and the second added proprietary protection for methodology to continuously monitor and adjust the screen lighting. The second patent also added methodology to compensate for other testing factors, such as room illumination and when patients view the vision test through a mirror (which is a common practice in eyecare practitioners’ offices worldwide).
According to the company, this proprietary technology provides an easy way to automatically standardize vision test lighting to a level recommended by the U.S. National Academy of Sciences and the U.S. Food and Drug Administration.
Dr. David Evans, inventor of this new methodology, is the founder of VectorVision, Inc., which Guardion acquired in 2017 and is now a wholly-owned subsidiary of the company. Dr. Evans is now a director and the chief science officer of Guardion.
ISVA Appoints Gary Esterow as Executive Director
The International Sports Vision Association (ISVA), an organization of optometrists, athletic trainers, therapists, physicians, and sports teams dedicated to evaluating, training, and improving vision performance in athletes, announced the appointment of Gary Esterow as executive director.
Mr. Esterow will assume the executive director position on a part-time basis, while still serving as executive director of The Neuro-Optometric Rehabilitation Association, International (NORA) and operating Esterow Communications, LLC, a consulting agency.
Membership in the ISVA is open to optometrists, physicians, therapists, athletic trainers, or other licensed professionals as well athletes, families, coaches, or other interested parties. ISVA also provides complimentary membership to students in a professional degree program or to residents in a post-graduate program.
What influence does a rebate have on the selection and prescribing of a contact lens?
Your Interesting Case Photo Here in the Next Issue
Have you seen an interesting case lately? Would you like to share it with your colleagues? An image from that case could appear in Contact Lenses Today in the coming weeks!
We welcome photo submissions from our other readers! It is easy to submit a photo for consideration for publishing in Contact Lenses Today. Simply visit http://www.cltoday.com/upload/upload.aspx to upload your image. Please include a detailed explanation of the photo and your full name, degree or title, and city/state/country.
It is always a joy to introduce the wonders of contact lenses (CLs) to a neophyte CL patient. Practitioners have the opportunity to educate their patients about CL options, care systems or the lack thereof, and general CL care. After patients successfully complete their application and removal training, they are free to try out their CLs at home. With some luck, these patients then return to their follow-up exams indicating that their expectations have been met and that they would like to finalize their CL prescription. While this is a CL practitioner’s general goal, what percentage of neophyte CL wearers actually continue wearing their CLs?
Sulley et al conducted a chart review to answer this question by analyzing the first year’s worth of wear in 524 neophyte CL patients (age range = 8 to 79 years old).1 The study authors found a retention rate of 74%, with spherical, toric, and multifocal CL wearers having retention rates of 79%, 73%, and 57%, respectively.1 When patients did drop out of CLs, they indicated that the primary factor was because of poor vision (distance or near), which was followed by discomfort and motivation.1
Sulley et al further determined that about half of all CL dropouts ceased CL use within two months.1 Children were the least likely age group to drop out of CLs.1 Patients fit in silicone hydrogel CLs were more likely to drop out of CLs compared with those fit in hydrogel CLs.1 Patients who had refractive errors between plano and +2.00D were more likely to drop out of CLs compared to other refractive error groups, and infrequent CL purchasing was associated with CL dropout.1 Interestingly, sex, practice type, astigmatic power, and replacement frequency were not associated with neophyte CL wearer success.1
This study suggests that vision is paramount and that it is important for practitioners to monitor patients early on in the CL fitting process because most new wearers who do drop out of CLs do so quickly after the initial fitting.1 The authors likewise found that few patients who dropped out of CLs were offered an alternative CL, which also suggests that new wearers’ success could be greatly improved by simply offering them an alternative option,1 a suggestion that is supported by Young et al who found that 73% of CL dropouts could be successfully refit into an alternative CL.2
1. Sulley A, Young G, Hunt C. Factors in the success of new contact lens wearers. Contact Lens Anterior Eye. 2017 Feb;40:15-24.
2. Young G, Veys J, Pritchard N, Coleman S. A multi-centre study of lapsed contact lens wearers. Ophthalmic Physiol Opt. 2002 Nov;22:516-527.
MATERIALS & DESIGNS
David L. Kading, OD
Jerry had come into the office four years ago and was fit into scleral lenses because of his high astigmatism. Since then, he has been faithful in coming back to the office for his visits and for minor modifications to his lens power and fit. Now, Jerry is 41 years old and is noting some eye strain at the end of the day.
How should a practitioner proceed with this case? Option 1: "Sorry, Jerry, time to go to glasses," or option 2: tackle a soft toric multifocal fitting?
Because Jerry was already so successful with contact lenses, he got "the talk." He was told about presbyopia and how what was happening would only get worse. "No, Jerry, you cannot have LASIK to fix this problem."
Because it was time to get a new pair of lenses anyway, it was suggested that we make some small adaptations to his scleral lenses to correct his near vision. Jerry was informed about the reality that the new lenses would be different from his current ones and that he might notice some alterations to his distance vision, but the alterations would be small and manageable. Measurements of his dominant eye and pupil size were called into the lab.
Over the next month, Jerry adapted to his lenses and only needed one modification to one of his lenses to help improve his distance vision slightly. Jerry was also informed that over the next couple of years, there would need to be some modifications that may further affect his distance vision, but that we are able to manufacture a separate pair of lenses that he can wear part time for distance activities. Most laboratories will give special pricing on lenses when ordered as a second pair for the same patient.
Jerry made the transition into multifocal scleral lenses very easily, but for other patients it may require additional time and effort. In the end, it’s worth every minute for both the practitioner and the patient.
Infectious Keratitis After Ocular Surface Stem Cell Transplantation
The purpose of this study was to describe the rate, clinical/microbiological characteristics, and outcomes of infectious keratitis in eyes with limbal stem cell deficiency after ocular surface stem cell transplantation (OSST).
In this retrospective chart review of 278 eyes that underwent OSST between Jan. 2006 and Dec. 2016, eyes treated for previous infectious keratitis (bacterial, fungal, or viral) were included. Demographics, risk factors, course, microbiological characteristics, and outcomes were assessed.
A total of 52 eyes (18.7%) of 48 patients (28 men and 20 women) developed 75 episodes (culture-proven or presumed) of infectious keratitis (range one to four episodes) with mean follow up of 5.3 ± 3.6 years after OSST. The most common limbal stem cell deficiency etiologies included chemical/thermal (27 episodes), Stevens-Johnson syndrome (19 episodes), aniridia (eight episodes), and mucous membrane pemphigoid (eight episodes). There were 44 (58.7%) bacterial keratitis episodes, 24 (32%) fungal keratitis episodes, and seven (9.3%) herpes simplex virus (HSV) keratitis episodes. Gram-positive bacteria (79%) and Candida species (73%) were the most common bacterial and fungal pathogens. Before infection, 33% had an epithelial defect, 69% had a bandage contact lens, 91% were on systemic immunosuppression, and 25% recently had undergone ocular surgery (< 3 months). Although 75% resolved with antimicrobial treatment, 25% required a therapeutic keratoplasty (TPK); two cases needed multiple TPK procedures.
The authors concluded that despite successful OSST surgery, infectious keratitis is relatively common, and aggressive medical/surgical therapy is warranted. Prophylactic topical antibiotics and a cicatrizing conjunctivitis diagnosis may account for the high proportion of fungal keratitis in this population.
Cheung AY, Sarnicola E, Eslani M, et al. Infectious Keratitis After Ocular Surface Stem Cell Transplantation. Cornea. 2018 Jul 10. [Epub ahead of print]